Seleniso Discontinuation Guidelines

Selinexor (Selinexor), as a highly effective oral anti-cancer drug, plays an important role in the treatment of multiple myeloma (MM) and acute myeloid leukemia (AML). It effectively restores the anti-tumor factor activity in cells by inhibiting the function of XPO1 protein, thereby powerfully inhibiting the growth and spread of cancer cells.

However, it is worth noting that treatment with selinesol requires strict compliance with medical instructions and long-term and continuous use. For anti-tumor drugs, sudden discontinuation is undoubtedly an extremely risky behavior. Especially in the field of chemotherapy and targeted therapy, tumor cells have extremely strong recovery ability. Once the effect of the drug is interrupted, they may rebound quickly, causing the disease to relapse or even worsen.

Although selinesol has relatively obvious side effects, the risk of stopping the drug without authorization is greater, especially for rapidly progressive diseases such as multiple myeloma and acute myeloid leukemia. During the period of taking medication, patients should always adjust their medication regimen according to changes in condition and drug tolerance under the guidance of their doctor.

If the patient encounters severe side effects or develops drug resistance, the doctor will adjust the drug dosage or change the treatment plan according to the actual situation. Therefore, when patients feel unwell, they should communicate with their doctor promptly and never decide to stop taking medication or change the medication time on their own.

Long-term persistence in taking the medicine according to the prescribed cycle is the key to ensuring the efficacy of selinesol. Sudden discontinuation of medication may lead to a sharp drop in drug concentration in the body, unsustainable efficacy, and may even prompt tumor cells to develop drug resistance, making subsequent treatment more difficult. Therefore, when taking selinesol, patients must follow the doctor's advice and adhere to treatment in order to obtain the best therapeutic effect.

xa0

Reference materials

Karyopharm TherapeuticsOfficial website:https://www.karyopharm.com

National Medical Products Administration (NMPA) official website:https://www.nmpa.gov.cn